These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
338 related items for PubMed ID: 16018804
1. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G, EPOKA-MASTER Study Group. BMC Infect Dis; 2005 Jul 14; 5():58. PubMed ID: 16018804 [Abstract] [Full Text] [Related]
7. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. AIDS; 2000 Dec 22; 14(18):2895-902. PubMed ID: 11153671 [Abstract] [Full Text] [Related]
8. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S. Clin Infect Dis; 2005 Feb 15; 40(4):588-93. PubMed ID: 15712082 [Abstract] [Full Text] [Related]
9. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan. Chou CC, Tsai HC, Wu KS, Sy CL, Chen JK, Chen YS, Lee SS. J Microbiol Immunol Infect; 2016 Aug 15; 49(4):546-53. PubMed ID: 25440980 [Abstract] [Full Text] [Related]
10. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatology; 2002 Jan 15; 35(1):182-9. PubMed ID: 11786975 [Abstract] [Full Text] [Related]
15. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET. Afr Health Sci; 2011 Mar 15; 11(1):16-23. PubMed ID: 21572852 [Abstract] [Full Text] [Related]
16. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC. PLoS One; 2017 Mar 15; 12(2):e0171596. PubMed ID: 28222098 [Abstract] [Full Text] [Related]
19. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, Maggiolo F, De Luca A, Paraninfo G, Antonucci F, Migliorino G, Lazzarin A, Di Perri G, Rizzardini G, Esposito R, Carosi G. Infection; 2009 Jun 15; 37(3):244-9. PubMed ID: 19471856 [Abstract] [Full Text] [Related]